Navigation Links
Two Antioxidant Vitamins Don't Protect Against Heart Disease
Date:11/11/2008

Study highlights:

- A major long-term study of more than 14,000 physicians showed no cardiovascular protection from two antioxidant vitamins taken by much of the American population.

- Taken individually, vitamins E and C failed to protect against heart and blood vessel disease.

NEW ORLEANS, Nov. 11 /PRNewswire-USNewswire/ -- Vitamins E and C -- antioxidant supplements taken by many American adults -- don't protect against cardiovascular disease when taken individually, according to a long-term study of more than 14,000 male physicians presented at the American Heart Association's Scientific Sessions 2008. Results of the Physician's Health Study II (PHS II) were presented as a late-breaking clinical trial. The study was simultaneously published in the Journal of the American Medical Association.

"We found no compelling evidence that either individual vitamin E or vitamin C reduces the risk of cardiovascular disease," said J. Michael Gaziano, M.D., M.P.H., principal investigator of the study and a cardiologist at Brigham and Women's Hospital and VA Boston Healthcare System in Boston, Mass.

Gaziano said results of the study add to the growing consensus about vitamin E's lack of cardiovascular protection based on several earlier trials that failed to find any effect.

The randomized, double-blind, placebo-controlled trial included 14,641 U.S. physicians 50 and older. Cardiovascular disease in the study included nonfatal heart attack, nonfatal stroke and fatal cardiovascular disease

"This is one of the first large-scale, long-term clinical trials of individual vitamin C supplementation in the prevention of cardiovascular disease," said Howard D. Sesso, Sc.D., M.P.H., co-author and project director of PHS II and assistant professor of medicine at Brigham and Women's Hospital.

Unlike several earlier studies in which vitamins E and C were often given as part of an antioxidant cocktail, this study investigated the two vitamins individually, he said.

The findings are an example of the importance of randomized clinical trials to test promising hypotheses generated by laboratory or observational research, Sesso said. Antioxidant vitamins appeared promising in previous laboratory research and in observational human studies, in which people who reported eating a diet rich in vitamins E and C seemed to have fewer cardiovascular problems.

Fruits and vegetables may provide some protective effect beyond the vitamins they contain, or it could be that people who report eating a lot of fruits and vegetables have other characteristics that lead to better health, Sesso said.

Therefore, researchers needed a large, well-designed, placebo-controlled clinical trial -- one that included a dedicated group of participants.

Each year, the investigators mailed participants calendar packs containing each vitamin or its placebo, depending upon the group to which each physician had been randomly assigned. The doses used in the study (400 international units of vitamin E every other day and 500 milligrams of vitamin C daily) correspond to typical amounts available commercially, Gaziano said.

During an average eight years of follow-up, participants provided annual updates on compliance, various risk factors and health outcomes, allowing the investigators access to their medical records when necessary to confirm cardiovascular events or cause of death.

"Broadly speaking, there has been great interest in antioxidants in the prevention of cardiovascular disease," said Sesso. "Despite promising findings from laboratory research and observational studies, our results from PHS II point to the need for large-scale, long-term clinical trials testing the antioxidant hypothesis."

The final arm of PHS II, testing daily multivitamin supplementation, is ongoing.

Individual author disclosures are available on the abstract.

The study was funded by grants from the National Institutes of Health in Bethesda, Md., and an investigator-initiated grant from BASF Corporation in Florham Park, N.J. BASF Corporation, Wyeth Pharmaceuticals in Madison, N.J., and DSM Nutritional Products, Inc., formerly Roche Vitamins, in Parsippany, N.J., provided study agents and packaging.

Statements and conclusions of study authors that are presented at American Heart Association scientific meetings are solely those of the study authors and do not necessarily reflect association policy or position. The association makes no representation or warranty as to their accuracy or reliability. The association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations are available at http://www.americanheart.org/corporatefunding.


'/>"/>
SOURCE American Heart Association
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Susan Lark, MD Develops a Powerful ORAC Drink Packed with the Antioxidant Power of Nine Fruits
2. Too Much Sun, Too Few Antioxidants Spell Eye Trouble
3. Sunlight exposure plus low antioxidant levels may place older adults at risk for eye disease
4. Antioxidant-Rich Diet May Protect Against Eye Disease
5. Green Tea Antioxidant May Help Prevent Alzheimers
6. Antioxidant supplements may lessen benefit of radiation and chemotherapy
7. Cancer Patients Should Steer Clear of Antioxidants
8. New Antioxidant Drug Shows Promise Against Diabetes
9. Blueberry Juice Tops The ORAC Antioxidant Chart
10. Determined a new method to establish the antioxidant capacity of extra virgin olive oil
11. Dr. William S. Gruss, M.D., Says That Medical Research Shows You Can Reduce Your Risk of Cancer By Up To 77% and Reverse the Effects of Aging in A CARDIOLOGISTS GUIDE TO ... ANTI-AGING, ANTIOXIDANTS & RESVERATROL
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... , ... June 28, 2017 , ... ... announce that its 50ml Liquid Stevia Sweet Drops™ have received the Non-GMO Project ... verification process from the Non-GMO Project, the only third-party verification for non-GMO foods ...
(Date:6/28/2017)... IL (PRWEB) , ... June 28, 2017 , ... Eating ... shows that every 62 minutes, at least one person dies as a direct result ... a greater need exists for qualified treatment providers. The iaedp Foundation meets this challenge ...
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/27/2017)... Jupiter, Fla. (PRWEB) , ... June 27, 2017 ... ... Integration™, today announced the appointment of Mike Finnegan to the position of Executive ... 25 years of experience in healthcare technology, telehealth and medical device sales leadership. ...
(Date:6/27/2017)... ... ... The Congressional Budget Office (CBO) projects that the Better Care Reconciliation Act (BCRA), ... Care Act (ACA), would result in 22 million Americans losing their health insurance by ... 20 million Americans have gained health insurance under the ACA, and from 2013 to ...
Breaking Medicine News(10 mins):
(Date:5/26/2017)... International plc (NASDAQ: ENDP ) announced today that ... Company in a fireside chat at Goldman Sachs, 38 th ... at 10:40 a.m. PT / 1:40 p.m. ET. The conference ... Palos Verdes, CA. A live webcast ... the Company,s website at http://www.endo.com/investors/overview . Participants should allow ...
(Date:5/24/2017)... , May 24, 2017  ivWatch LLC ... Equipment Manufacturer (OEM) Board to enable seamless integration ... patient monitoring systems, infusion pumps and other devices. ... will be able to help health care customers ... reduced risks related to IV therapy. ...
(Date:5/22/2017)... VALLEY COTTAGE, N.Y. , May 22, 2017 ... natural antiviral treatment Gene-Eden-VIR/Novirin, announces the launch of ... in plain English, the results of a clinical ... after one year treatment with Gene-Eden-VIR/Novirin in individuals ... is important to note that there are no ...
Breaking Medicine Technology: